Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABEO vs YMAT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABEO Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

ABEO Overall Winner 6-Pillar Tally: ABEO 5 – 0 YMAT (1 Tie) Matrix Metrics: ABEO 7 – 3 YMAT

As of Nov 16, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over J-Star Holding Co., Ltd. (YMAT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABEO carries a Unified Composite Score of 48.7/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin), whereas YMAT carries 57.8/100 (HOLD) at $0.89 (N/M Forward P/E, -372.2% operating margin).

  • Composite vs. Pillar Nuance: While YMAT currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ABEO 48.7/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. -372.2% operating margin) and revenue trajectory (+2745.0% vs. -36.1% YoY).
  • Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.3); meanwhile YMAT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABEO vs YMAT
ABEO NASDAQ Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.60
+7.44% 1D
Market Cap $149.2M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 149% Vol
Unified Composite Score
48.7 / 100 HOLD
Tech 50.0 Fund 51.0 Flow 67.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.6%), weak momentum, RSI 23
RSI-14: 23.3 · SMA20: $3.77 · SMA50: $4.63
YMAT NASDAQ
J-Star Holding Co., Ltd. Ordinary Shares
Sporting & Athletic Goods, Nec
$0.89
-16.02% 1D
Market Cap $4.8M
TTM Revenue $6.1M
Forward P/E N/M
Beta / 30D Vol 5.73β · 218% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 75.0 Fund 59.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.2%), weak momentum, RSI 40
RSI-14: 39.8 · SMA20: $1.58 · SMA50: $1.59

6-Pillar Scorecard Institutional Category Breakdown (ABEO 5 – 0 YMAT)

Columns: Metric · ABEO · YMAT
1. Valuation Multiples ABEO
Forward P/E 18.7x N/M
Trailing P/E 18.7x N/M
PEG Ratio N/M N/M
EV / Revenue 2.6x 0.8x
2. Growth & Scale ABEO
Revenue Growth (YoY) +2745.0% -36.1%
Earnings Growth (YoY) +0.0% -56.4%
TTM Revenue (USD) $39M $6.1M
Market Cap $149.2M $4.8M
3. Profitability & Quality ABEO
Gross Margin -3.5% 57.0%
Operating Margin -186.1% -372.2%
Net Profit Margin -160.3% 0.0%
Return on Equity (ROE) -42.1% -275.9%
4. Balance Sheet & Cash Flow ABEO
Cash Generation (TTM) -$66M -$22M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $50M Net Cash $0.64 Book/Sh · -275.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABEO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 165.8% (27th %ile) N/A (N/A)
Put/Call OI Skew 0.19x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Specialty Chemicals Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABEO (7) vs YMAT (3)
Institutional Metric ABEO YMAT Criterion Row Edge
Market Capitalization
Scale
$149.2M $4.8M Larger Scale ABEO
Trailing P/E Ratio
Valuation
18.7x N/M Lower Multiple ABEO
Forward P/E Ratio
Valuation
18.7x N/M Lower Multiple ABEO
Revenue Growth (YoY)
Growth
+2745.0% -36.1% Higher Growth ABEO
Operating Margin (TTM)
Profitability
-186.1% -372.2% Higher Margin ABEO
Net Profit Margin
Profitability
-160.3% 0.0% Higher Margin YMAT
Return on Equity (ROE)
Capital Efficiency
-42.1% -275.9% Higher ROE ABEO
52-Week Range Position
Momentum
9% ($2–$8) 15% ($0–$4) Stronger Trend YMAT
Beta / 30D Volatility
Risk Regime
0.60β · 149% Vol 5.73β · 218% Vol Lower Realized Risk ABEO
Unified Institutional Score
Composite Signal
48.7 / 100 (HOLD) 57.8 / 100 (HOLD) Higher Composite YMAT
Trailing 12M Revenue (USD)
Operating Scale
$39M $6.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-3.5% 57.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.6x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($50M Net Cash) -$22M EBITDA ($0.64 Book/Sh · -275.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon YMAT +9.26 pp
ABEO: -41.31% · YMAT: -32.05%
3M Horizon YMAT +4.4 pp
ABEO: -57.79% · YMAT: -53.39%
6M Horizon YMAT +14.71 pp
ABEO: -51.58% · YMAT: -36.87%
1Y Horizon YMAT +49.72 pp
ABEO: -42.6% · YMAT: +7.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABEO vs YMAT. Trailing 12-month operating profitability (ABEO -186.1% vs YMAT -372.2%) and valuation multiples (ABEO 18.7x vs YMAT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABEO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin-3.5%
Op. Margin-186.1%
ROE / Fwd P/E-42.1% · 18.7x
YMAT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.1M
Gross Margin57.0%
Op. Margin-372.2%
ROE / Fwd P/E-275.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABEO BREAKDOWN
67d in phase · OBV DISTRIBUTION
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
YMAT BREAKDOWN
83d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact YMAT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $149.2M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
YMAT Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $4.8M market capitalization and -372.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABEO vs YMAT Key Questions & Quantitative Answers

As of Nov 16, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over J-Star Holding Co., Ltd. (YMAT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABEO carries a Unified Composite Score of 48.7/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin), whereas YMAT carries 57.8/100 (HOLD) at $0.89 (N/M Forward P/E, -372.2% operating margin). Composite vs. Pillar Nuance: While YMAT currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ABEO 48.7/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. -372.2% operating margin) and revenue trajectory (+2745.0% vs. -36.1% YoY). Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.3); meanwhile YMAT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: ABEO posts +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin), compared with YMAT at -36.1% YoY revenue growth and -56.4% YoY earnings growth on $6.1M TTM revenue (57.0% gross margin, -372.2% operating margin). On trailing 12-month operating scale, ABEO generates $39M in USD-normalized revenue versus $6.1M for YMAT. In operating R&D and SG&A reinvestment, ABEO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for YMAT.

ABEO screens cheaper on headline valuation multiples. ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin), whereas YMAT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABEO (-42.1% ROE) versus YMAT (-275.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk). By comparison, YMAT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (5.73β · 218% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.